Diffuse alveolar damage following a single administration of a cyclophosphamide containing chemotherapy regimen [5]

Australian and New Zealand Journal of Medicine

Volumn 27, Issue 5, 1997, Pages 605-606

  Woolley, I ^a   Collett, J ^b   Goldstein, D ^a  

^a FAIRFIELD HOSPITAL   (Australia)

^b AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIRUBICIN; METOCLOPRAMIDE; VINCRISTINE;

ADULT; AUTOPSY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CLINICAL FEATURE; FATALITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LETTER; LUNG INJURY; LUNG TOXICITY; MALE; T CELL LYMPHOMA;

EID: 0030831795     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1997.tb00981.x     Document Type: Letter

References (8)

1. Mujar MF. Pulmonary toxicity of anti-tumour agents. Cancer Treat Rev 1983; 10: 221-43.
2. Myers JL. Pathology of drug induced lung disease. In: Katzenstein AL, Askin FB (Eds). Surgical pathology of non-neoplastic lung disease. Philadelphia: WB Saunders & Co, 1992: 97-123.
3. Cooper JA, White DA, Matthay RA. Drug induced pulmonary disease. Am Rev Respir Dis 1986; 133: 321-40.
4. Maxwell I. Reversible pulmonary oedema following cyclophosphamide treatment. JAMA 1974; 229: 13728.
5. Kramer S, Leventhal JM, Hutchinson TA, Feinstein AR. An algorithm for the operational assessment of adverse drug reactions. JAMA 1979; 242: 623-31.
6. Sappino AP, Seelentag W, Pelte MF, Alberto P, Vassalli P. Tumor necrosis factor cachectin and lymphotoxin gene expression in lymph nodes from lymphoma patients. Blood 1990; 75: 958-62.
7. Piguet PF, Collart MA, Garu GE, Kapanci Y, Vassalli P. Tumour necrosis factor cachectin plays a key role in bleomycin induced pneumopathy and fibrosis. J Exp Med 1989; 170: 694-700.
8. Chiche D, Pico JL, Bernaudin JF et al. Pulmonary edema and shock after high dose aracytidine-C for lymphoma: possible role of tNF-alpha and PAF. Eur Cytokine Netw 1993; 4: 147-51.